Physician profile
David Eugene Mcneely
NPI 1285952705
$77,692.39
in general payments reported to CMS, 2019-2025
37 companies · $2,330 in 2025
The $2,330 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $21K · 2021: $15K · 2022: $3,820 · 2023: $6,803 · 2024: $14K · 2025: $2,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,042 · Consulting Fee: $7,950 · Travel and Lodging: $4,778 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,042.24 |
| Consulting Fee | $7,950.00 |
| Travel and Lodging | $4,778.27 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,539.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $51,088.35 | 2019-2025 | Farxiga |
| Edwards Lifesciences Corporation | $10,142.28 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Evoque |
| Abbott Laboratories | $8,438.48 | 2019-2025 | Mitraclip, Cardiomems, Triclip |
| Boston Scientific Corporation | $2,191.93 | 2019-2025 | Watchman Flx, Farapulse, Watchman Access System |
| Novartis Pharmaceuticals Corporation | $1,080.33 | 2019-2025 | |
| Heartflow, INC. | $650.43 | 2024 | |
| Amgen INC. | $474.36 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $465.97 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $446.22 | 2019-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $299.92 | 2023-2025 | Onpattro |
| Siemens Medical Solutions USA, INC. | $236.04 | 2021-2024 | Magnetom Sola, System Somatom Drive |
| Astellas Pharma US INC | $177.96 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $174.56 | 2019-2024 | Xarelto |
| Impulse Dynamics (USA) INC. | $172.76 | 2023 | Optimizer |
| E.R. Squibb & Sons, L.L.C. | $166.15 | 2022-2025 | Camzyos |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $162.16 | 2019-2022 | |
| Abiomed | $149.56 | 2022-2024 | Impella |
| Trisalus Life Sciences, INC. | $139.77 | 2025 | Trinav Infusion System |
| Bayer Healthcare Pharmaceuticals INC. | $131.10 | 2021-2025 | |
| Philips North America LLC | $130.14 | 2023-2025 | (5091) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided, (Cm9) Amb Mon & Diag Und |
| Actelion Pharmaceuticals US, INC. | $122.64 | 2022 | |
| Merck Sharp & Dohme LLC | $111.28 | 2023-2025 | Verquvo |
| Atricure, INC. | $102.98 | 2024 | |
| Teleflex LLC | $79.82 | 2025 | Trapliner, Turnpike |
| Kiniksa Pharmaceuticals International, Plc | $55.88 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, Ltd. | $46.32 | 2022-2023 | Arcalyst |
| Novo Nordisk INC | $43.02 | 2022 | |
| Terumo Medical Corporation | $31.69 | 2025 | Angio-Seal, Metacross Otw |
| Esperion Therapeutics, INC. | $30.53 | 2020-2021 | |
| Daxor Corporation | $25.45 | 2025 | Bva-100 |
| Amarin Pharma, INC. | $24.47 | 2020 | |
| Cardiovascular Systems INC. | $23.00 | 2020-2021 | |
| Cvrx, INC. | $20.98 | 2025 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $16.04 | 2024 | |
| Convatec INC. | $14.45 | 2022 | |
| Medtronic, INC. | $13.31 | 2023 | Plasmablade(Tm) |
| Chiesi USA, INC. | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mcneely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.